CLVSQ
CLOVIS ONCOLOGY INC
stock OTC

clovis oncology a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the united states, europe and additional international markets. the company's development programs are targeted at specific subsets of the cancer population, combining personalized medicine with companion diagnostics to direct products to those patients most likely to benefit from their use. we have three product candidates in clinical development: rociletinib (co-1686), which is in development for the treatment of non-small cell lung cancer; rucaparib, in development for the treatment of ovarian cancer and other solid tumors; and lucitanib, which is in development for the treatment of breast cancer and other solid tumors. we maintain global rights for rociletinib and rucaparib, and u.s. and japanese rights to lucitanib.